BioMarin CEO says study results for hemophilia gene therapy are as 'good as we could hope'
Share

BioMarin CEO says study results for hemophilia gene therapy are as 'good as we could hope'

Jean-Jacques Bienaime, CEO and chairman of BioMarin Pharmaceutical, appeared on Tuesday's episode of "Mad Money," discussing trial results for the company's hemophilia gene therapy.
02:40
Tue, Jan 11 20227:18 PM EST